Latest News

View All Recent News »

Alimera Sciences Provides Details On FDA Approval Of ILUVIEN® As The First Long-Term Treatment For Diabetic Macular Edema

September 29, 2014 -- Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will hold a conference call to provide...

Read More »

Alimera Sciences Receives FDA Approval For ILUVIEN®, The First Long-Term Treatment For Diabetic Macular Edema

September 26, 2014 -- Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has...

Read More »

Alimera Sciences' ILUVIEN® Receives Tenth National Marketing Authorization For The Treatment Of Chronic Diabetic Macular Edema

September 03, 2014 -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Swedish Medical Products Agency has granted...

Read More »